Pertussis vaccination during pregnancy: Antibody persistence in infants.
Maternal pertussis vaccination is associated with higher levels of pertussis antibodies at birth. We assessed the persistence of pertussis antibodies until primary vaccination in infants whose mothers received Tdap (tetanus, diphtheria, acellular pertussis) vaccine during pregnancy. Infants were born at the Hospital Clinic of Barcelona (Spain) in November 2014. Anti-PT IgG was determined by ELISA at delivery, between the first and second month of life, and estimated at 2months of age. The study included 37 infants whose mothers received Tdap between 21 and 38weeks of gestation. Infants presented a decline in GMC of anti-PT IgG between peripartum and follow-up levels, 52.7 (95% CI 34.7-80.2) versus 7.5 (95% CI 4.2-13.3) at 2months of age (p<0.001). The median half-life of maternal antibodies was 47days. More than half (51.4%) the infants presented detectable anti-PT IgG before the start of primary infant vaccination.
Department of Preventive Medicine and Epidemiology, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. Electronic address: albavilajeliu@gmail.com.
Alba
A
Vilajeliu
Department of Maternal-Fetal Medicine, BCNatal - Barcelona Center of Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Laia
L
Ferrer
Department of Maternal-Fetal Medicine, BCNatal - Barcelona Center of Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Jordina
J
Munrós
Department of Maternal-Fetal Medicine, BCNatal - Barcelona Center of Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Anna
A
Goncé
Department of Maternal-Fetal Medicine, BCNatal - Barcelona Center of Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Marta
M
López
Department of Microbiology, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.
Josep
J
Costa
Department of Preventive Medicine and Epidemiology, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
José M
JM
Bayas
D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000627:therapeutic use*; D005260:Female; D006207:Half-Life; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008297:Male; D011247:Pregnancy; D011446:Prospective Studies; D014917:Whooping Cough / Q000517:prevention & control*; D055815:Young Adult
D000907:Antibodies, Bacterial; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D007074:Immunoglobulin G
Antibody persistence; Infant vaccination; Maternal vaccination; Neonatal pertussis